Irina G. Smolentseva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Irina G. Smolentseva has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Oleg S. Levin
Russian Medical Academy of Continuous Professional Education
7 shared publications - Marina A. Samushiya
Central State Medical Academy of the Department of Presidential Affairs of the Russian Federation
3 shared publications - Natalia V. Fedorova
Russian Medical Academy of Continuous Professional Education
3 shared publications - A. V. Goryunov
Russian Mental Health Research Center
2 shared publications - A.V. Kuzmina
Russian Medical Academy of Continuing Professional Education
2 shared publications - Anna A. Gamaleya
N. N. Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia
2 shared publications
Latest Publications
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Validation of a scale for deciding on the referral of patients with Parkinson’s disease to a competence center for selection for interventional therapies
Objective. To validate a Russian-language questionnaire scale for quick evaluation and decision-making regarding the referral of patients diagnosed with Parkinson’s disease (PD) to specialized centers for assessment and selection for interventional therapies (IT). Material and methods. This study involves a diagnostic evaluation of a scale developed to quickly identify PD patients who may require referral to specialized centers for IT selection. A total of 100 patients with PD were assessed; 72 required ongoing monitoring and/or optimization of pharmacological treatment, while 28 were deemed suitable candidates based on the CAPSIT-PD criteria. The study analyzed the scale’s reliability and its convergent and discriminant validity. Results. The validation process revealed that the scale demonstrated high reliability in identifying patients with advanced PD who may be appropriate candidates for IT. The predictive model, developed through binary logistic regression, demonstrated an area under the ROC curve of 0.84 (95% CI 0.74—0.93) in predicting the probability of identifying suitable candidates. Furthermore, the model achieved a sensitivity of 75.0% (21 of 28 patients) and a specificity of 93.1% (67 of 72 patients). The sensitivity and specificity of the IT-PD scale—used to select candidates for interventional therapy—were evaluated at a threshold of 11 points or higher, yielding 89.3% and 91.7%, respectively. Conclusions. The concise and user-friendly IT-PD score effectively assesses the critical criteria for selecting candidates for interventional therapy, thereby supporting timely referral decisions to specialized centers.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Validation of a scale for deciding on the referral of patients with Parkinson’s disease to a competence center for selection for interventional therapies
Objective. To validate a Russian-language questionnaire scale for quick evaluation and decision-making regarding the referral of patients diagnosed with Parkinson’s disease (PD) to specialized centers for assessment and selection for interventional therapies (IT). Material and methods. This study involves a diagnostic evaluation of a scale developed to quickly identify PD patients who may require referral to specialized centers for IT selection. A total of 100 patients with PD were assessed; 72 required ongoing monitoring and/or optimization of pharmacological treatment, while 28 were deemed suitable candidates based on the CAPSIT-PD criteria. The study analyzed the scale’s reliability and its convergent and discriminant validity. Results. The validation process revealed that the scale demonstrated high reliability in identifying patients with advanced PD who may be appropriate candidates for IT. The predictive model, developed through binary logistic regression, demonstrated an area under the ROC curve of 0.84 (95% CI 0.74—0.93) in predicting the probability of identifying suitable candidates. Furthermore, the model achieved a sensitivity of 75.0% (21 of 28 patients) and a specificity of 93.1% (67 of 72 patients). The sensitivity and specificity of the IT-PD scale—used to select candidates for interventional therapy—were evaluated at a threshold of 11 points or higher, yielding 89.3% and 91.7%, respectively. Conclusions. The concise and user-friendly IT-PD score effectively assesses the critical criteria for selecting candidates for interventional therapy, thereby supporting timely referral decisions to specialized centers.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Levodopa/carbidopa/entacapone combination in chronotherapy of Parkinson’s disease
Objective. To evaluate the efficacy of the levodopa/carbidopa/entacapone combination in the chronotherapy of Parkinson’s disease (PD). Material and methods. This multicenter study was conducted at seven clinical sites, with 72 patients completing the follow-up period. The efficacy of levodopa/carbidopa/entacapone administration was evaluated in relation to the daily activity profile of levodopa. Patients recorded hourly assessments of «on», «off», and dyskinesia periods in a diary before and after therapy adjustment. The follow-up period lasted one month. Results. Patients misidentified «on» periods in 46% of cases and «off» periods in 35% of cases. The daily profile of levodopa efficacy was heterogeneous: the favorable period occurred in the morning for 40% of patients, in the afternoon for 32%, in the evening for 21%, and in the late evening for 7%. Tailoring levodopa/carbidopa/entacapone administration to the circadian profile improved outcomes in 72% of patients. A morning peak in efficacy predicted high drug sensitivity, while shifting the favorable period to the evening was associated with lower therapy efficacy. Conclusions. Optimizing the timing of antiparkinsonian drug administration in accordance with the circadian rhythm of PD symptoms may enhance therapeutic efficacy. Chronotherapy that incorporates the circadian profile of levodopa efficacy can maximize the benefits of levodopa/carbidopa/entacapone combination therapy.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Levodopa/carbidopa/entacapone combination in chronotherapy of Parkinson’s disease
Objective. To evaluate the efficacy of the levodopa/carbidopa/entacapone combination in the chronotherapy of Parkinson’s disease (PD). Material and methods. This multicenter study was conducted at seven clinical sites, with 72 patients completing the follow-up period. The efficacy of levodopa/carbidopa/entacapone administration was evaluated in relation to the daily activity profile of levodopa. Patients recorded hourly assessments of «on», «off», and dyskinesia periods in a diary before and after therapy adjustment. The follow-up period lasted one month. Results. Patients misidentified «on» periods in 46% of cases and «off» periods in 35% of cases. The daily profile of levodopa efficacy was heterogeneous: the favorable period occurred in the morning for 40% of patients, in the afternoon for 32%, in the evening for 21%, and in the late evening for 7%. Tailoring levodopa/carbidopa/entacapone administration to the circadian profile improved outcomes in 72% of patients. A morning peak in efficacy predicted high drug sensitivity, while shifting the favorable period to the evening was associated with lower therapy efficacy. Conclusions. Optimizing the timing of antiparkinsonian drug administration in accordance with the circadian rhythm of PD symptoms may enhance therapeutic efficacy. Chronotherapy that incorporates the circadian profile of levodopa efficacy can maximize the benefits of levodopa/carbidopa/entacapone combination therapy.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Neurodegeneration with brain iron accumulation type 4
Neurodegeneration with brain iron accumulation (NBIA) is a heterogeneous group of hereditary disorders characterized by iron accumulation in the brain, predominantly affecting the basal ganglia. These conditions present with multisystem clinical manifestations, most notably motor, cognitive, and behavioral disorders. To date, ten variants of NBIA have been identified, with BPAN, PKAN, and PLAN being the most common. This report presents five confirmed cases of type 4 NBIA, termed mitochondrial membrane protein-associated neurodegeneration (MPAN), detailing clinical and neuroimaging findings and its molecular genetic characteristics; MPAN is associated with mutations in the C19orf12 gene encoding a mitochondrial membrane protein.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Neurodegeneration with brain iron accumulation type 4
Neurodegeneration with brain iron accumulation (NBIA) is a heterogeneous group of hereditary disorders characterized by iron accumulation in the brain, predominantly affecting the basal ganglia. These conditions present with multisystem clinical manifestations, most notably motor, cognitive, and behavioral disorders. To date, ten variants of NBIA have been identified, with BPAN, PKAN, and PLAN being the most common. This report presents five confirmed cases of type 4 NBIA, termed mitochondrial membrane protein-associated neurodegeneration (MPAN), detailing clinical and neuroimaging findings and its molecular genetic characteristics; MPAN is associated with mutations in the C19orf12 gene encoding a mitochondrial membrane protein.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 120-125
Clinical and kinematic analysis of swimming disorders in Parkinson’s disease
Background. Recently, there has been an increase in swimming disorders among patients with Parkinson’s disease (PD), resulting in a partial or complete loss of this motor skill. The study of these disorders is of considerable scientific and practical interest, since they can significantly limit daily activity, reduce the quality of life, and increase the risk of drowning. Objective. To analyze the prevalence and conduct a clinical and kinematic study of swimming disorders in patients with Parkinson’s disease. Material and methods. The study included 100 patients with Hoehn & Yahr stage I—III PD. The patients were divided into two groups: those with impaired swimming (n=67) and those without impaired swimming (n=33). The groups were comparable in terms of gender, age, and disease duration and stage (p>0.05). The patients of the test group significantly differed from the comparison group due to more severe motor impairments in Part III of the MDS-UPDRS scale (p=0.033) and reduced daily activity according to the Schwab & England Activities of Daily Living Scale, p=0.041. Swimming assessment methods included the following: all participants performed video recording of swimming in the pool with synchronous recording of movements using inertial sensors (accelerometer+gyroscope) and underwater video cameras. Additional methods included clinical and neurological examination and assessment with standard scales (MDS-UPDRS, Schwab & England, scales for assessing cognitive and affective functions). Results. Our study indicated that swimming disorders are common symptoms of Parkinson’s disease and may develop early on. The study established a link between swimming-related motor disorders and axial motor disorders. Further research is needed to study this unusual manifestation in detail and the methods for its treatment.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 120-125
Clinical and kinematic analysis of swimming disorders in Parkinson’s disease
Background. Recently, there has been an increase in swimming disorders among patients with Parkinson’s disease (PD), resulting in a partial or complete loss of this motor skill. The study of these disorders is of considerable scientific and practical interest, since they can significantly limit daily activity, reduce the quality of life, and increase the risk of drowning. Objective. To analyze the prevalence and conduct a clinical and kinematic study of swimming disorders in patients with Parkinson’s disease. Material and methods. The study included 100 patients with Hoehn & Yahr stage I—III PD. The patients were divided into two groups: those with impaired swimming (n=67) and those without impaired swimming (n=33). The groups were comparable in terms of gender, age, and disease duration and stage (p>0.05). The patients of the test group significantly differed from the comparison group due to more severe motor impairments in Part III of the MDS-UPDRS scale (p=0.033) and reduced daily activity according to the Schwab & England Activities of Daily Living Scale, p=0.041. Swimming assessment methods included the following: all participants performed video recording of swimming in the pool with synchronous recording of movements using inertial sensors (accelerometer+gyroscope) and underwater video cameras. Additional methods included clinical and neurological examination and assessment with standard scales (MDS-UPDRS, Schwab & England, scales for assessing cognitive and affective functions). Results. Our study indicated that swimming disorders are common symptoms of Parkinson’s disease and may develop early on. The study established a link between swimming-related motor disorders and axial motor disorders. Further research is needed to study this unusual manifestation in detail and the methods for its treatment.
- 20 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 6-10
Musculoskeletal disorders in patients with Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that causes posture alterations with trunk anteflexion and the flexion of the hip and knee joints, leading to changes in the musculoskeletal system (MS). MS disorders in Parkinson’s Disease (PD) are linked to two primary mechanisms: they can be a direct result of the motor symptoms of PD and may also serve as early indicators of the disease. On one hand, clinically significant manifestations such as camptocormia, Pisa syndrome, anterocollis, and hand dystonia can lead to postural alterations and deformities of the fingers as the disease progresses. On the other hand, patients with Parkinson’s disease may also develop primary musculoskeletal disorders, including adhesive capsulitis and rotator cuff tendinopathy, which can result in partial tendon ruptures. Additionally, they are at risk for conditions like rheumatoid arthritis, osteoarthritis, osteoporosis, and pathological fractures. MS disorders are a significant disabling factor in PD patients, requiring an interdisciplinary approach. This approach involves neurologists, orthopedic traumatologists, and rehabilitation therapists to prevent disabling deformities, ensure early diagnosis, and provide optimal therapy. Therefore, it is essential to evaluate orthopedic symptoms in patients with Parkinson’s disease and conduct multicenter studies to develop management strategies.
- 20 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 6-10
Musculoskeletal disorders in patients with Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that causes posture alterations with trunk anteflexion and the flexion of the hip and knee joints, leading to changes in the musculoskeletal system (MS). MS disorders in Parkinson’s Disease (PD) are linked to two primary mechanisms: they can be a direct result of the motor symptoms of PD and may also serve as early indicators of the disease. On one hand, clinically significant manifestations such as camptocormia, Pisa syndrome, anterocollis, and hand dystonia can lead to postural alterations and deformities of the fingers as the disease progresses. On the other hand, patients with Parkinson’s disease may also develop primary musculoskeletal disorders, including adhesive capsulitis and rotator cuff tendinopathy, which can result in partial tendon ruptures. Additionally, they are at risk for conditions like rheumatoid arthritis, osteoarthritis, osteoporosis, and pathological fractures. MS disorders are a significant disabling factor in PD patients, requiring an interdisciplinary approach. This approach involves neurologists, orthopedic traumatologists, and rehabilitation therapists to prevent disabling deformities, ensure early diagnosis, and provide optimal therapy. Therefore, it is essential to evaluate orthopedic symptoms in patients with Parkinson’s disease and conduct multicenter studies to develop management strategies.
- 20 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 55-60
Parkinson’s Disease and Pregnancy. Resolution of The National Society for the Study of Parkinson’s Disease and Movement Disorders
Traditionally, Parkinson’s disease is considered a disease of old age. However, in 5—10% of patients, it is detected before the age of 40 years. This age is included in the childbearing period. Beliefs of the unwantedness of pregnancy, its impossibility, or the high risks associated with delivery are common. However, data on the course of pregnancy are limited and conflicting. Therefore, the development of evidence-based recommendations is an urgent task. In recent years, new data have been obtained regarding the course of pregnancy in patients with Parkinson’s disease, which are presented in this article.
- 20 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 55-60
Parkinson’s Disease and Pregnancy. Resolution of The National Society for the Study of Parkinson’s Disease and Movement Disorders
Traditionally, Parkinson’s disease is considered a disease of old age. However, in 5—10% of patients, it is detected before the age of 40 years. This age is included in the childbearing period. Beliefs of the unwantedness of pregnancy, its impossibility, or the high risks associated with delivery are common. However, data on the course of pregnancy are limited and conflicting. Therefore, the development of evidence-based recommendations is an urgent task. In recent years, new data have been obtained regarding the course of pregnancy in patients with Parkinson’s disease, which are presented in this article.
- 8 April 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (3) , 94-101
The effect of bilateral subthalamic nucleus deep brain stimulation on gait and balance in patients with Parkinson’s disease
Deep stimulation of the subthalamic nucleus (DBS STN) is a highly effective and relatively safety method of surgical treatment of Parkinson’s disease (PD), which can significantly reduce the motor symptoms of the disease (rigidity, tremor, hypokinesia), as well as levodopa-associated dyskinesia and fluctuations. However, the effect of DBS STN on axial symptoms, such as gait and postural stability, remains contentious. The searching for risk factors for worsening gait and balance disturbances in patients receiving DBS STN continues. Studies are being perfomed on the parameters of the DBS STN to reduce its negative impact on gait and balance.
- 8 April 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (3) , 94-101
The effect of bilateral subthalamic nucleus deep brain stimulation on gait and balance in patients with Parkinson’s disease
Deep stimulation of the subthalamic nucleus (DBS STN) is a highly effective and relatively safety method of surgical treatment of Parkinson’s disease (PD), which can significantly reduce the motor symptoms of the disease (rigidity, tremor, hypokinesia), as well as levodopa-associated dyskinesia and fluctuations. However, the effect of DBS STN on axial symptoms, such as gait and postural stability, remains contentious. The searching for risk factors for worsening gait and balance disturbances in patients receiving DBS STN continues. Studies are being perfomed on the parameters of the DBS STN to reduce its negative impact on gait and balance.
- 8 April 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (3) , 136-141
Schizophrenic spectrum disorders and Parkinson’s disease
The case demonstrated the difficulties of differential diagnosis and selection of therapy in patients with Parkinson’s disease and schizophrenic spectrum disorders. A clinical case of a 45-year-old male with a 10-year history of paranoid schizophrenia, with hallucinatory paranoid attacks and a steady increase in negative symptoms in the form of apato-abulic defect, is presented. The use of antipsychotics was associated with neuroleptic parkinsonism, well responding to therapy, and reduced when the patient discontinued antipsychotic therapy. However, after 10 years of schizophrenia, Parkinson’s syndrome manifested without neuroleptics; the antipsychotic therapy led to a sharp deterioration in motor status. A neurologist specializing in extrapyramidal disorders made the following diagnosis: Parkinson’s disease, mixed form, Hoehn and Yahr stage 2. According to the neurologist’s recommendation, typical neuroleptics were replaced with quetiapine, and levodopa was added to therapy. During treatment, the parkinsonism symptoms significantly decreased without an increase in psychotic symptoms. The clinical case illustrates the challenges in diagnosing Parkinson’s disease in a patient with schizophrenia and the complexity of treating such comorbidities. When managing such patients, close collaboration between psychiatrists and neurologists is necessary to make an accurate diagnosis and select the optimal therapy. The introduction of the multidisciplinarity principle will make it possible to achieve the fastest diagnosis and selection of balanced therapy in this category of patients.
- 8 April 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (3) , 136-141
Schizophrenic spectrum disorders and Parkinson’s disease
The case demonstrated the difficulties of differential diagnosis and selection of therapy in patients with Parkinson’s disease and schizophrenic spectrum disorders. A clinical case of a 45-year-old male with a 10-year history of paranoid schizophrenia, with hallucinatory paranoid attacks and a steady increase in negative symptoms in the form of apato-abulic defect, is presented. The use of antipsychotics was associated with neuroleptic parkinsonism, well responding to therapy, and reduced when the patient discontinued antipsychotic therapy. However, after 10 years of schizophrenia, Parkinson’s syndrome manifested without neuroleptics; the antipsychotic therapy led to a sharp deterioration in motor status. A neurologist specializing in extrapyramidal disorders made the following diagnosis: Parkinson’s disease, mixed form, Hoehn and Yahr stage 2. According to the neurologist’s recommendation, typical neuroleptics were replaced with quetiapine, and levodopa was added to therapy. During treatment, the parkinsonism symptoms significantly decreased without an increase in psychotic symptoms. The clinical case illustrates the challenges in diagnosing Parkinson’s disease in a patient with schizophrenia and the complexity of treating such comorbidities. When managing such patients, close collaboration between psychiatrists and neurologists is necessary to make an accurate diagnosis and select the optimal therapy. The introduction of the multidisciplinarity principle will make it possible to achieve the fastest diagnosis and selection of balanced therapy in this category of patients.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 73-80
Clinical presentation and diagnosis of Parkinson’s disease in patients with schizophrenia spectrum disorders
Objective. To study the features of the clinical picture and diagnosis of Parkinson’s disease (PD) in patients with schizophrenia spectrum disorders (SSD). Material and methods. The analysis of databases of four psychoneurological dispensaries in Moscow with the allocation of groups of patients with diagnoses of SSD (F20—F25 according to ICD-10) was carried out. Among these groups, a targeted search for patients with an established diagnosis of PD (G20) was conducted. Among this category of patients, the incidence of PD, the therapy taken, the premotor symptoms of PD and the parameters characterizing the features of the clinical picture and diagnosis of PD were analyzed. Results. A total of 9124 patients with SSD were identified, among them 11 people diagnosed with PD, while the final incidence of PD was 0.1% (95% CI 0—0.2%). The average age at onset of SSD and PD was 33.18±8.72 years and 58.9±8.1 years, respectively. The average time between the appearance of the first signs of PD and the final diagnosis was 5.09±1.92 years. The most commonly used antipsychotic in the group of patients with PD was quetiapine (54.5%); clozapine and some typical antipsychotics were used less frequently. The most common premotor symptoms were apathy, depression, anxiety, constipation and orthostatic hypotension. Hyposmia and behavioral disorders in the REM sleep phase were less common. Conclusion. The results confirm the difficulty of managing patients with comorbidity of PD and SSD. Psychiatrists should pay close attention to the features of motor symptoms in patients with SSD and carefully identify clinical signs that may indicate the presence of PD or other neurodegenerative diseases with parkinsonism.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 73-80
Clinical presentation and diagnosis of Parkinson’s disease in patients with schizophrenia spectrum disorders
Objective. To study the features of the clinical picture and diagnosis of Parkinson’s disease (PD) in patients with schizophrenia spectrum disorders (SSD). Material and methods. The analysis of databases of four psychoneurological dispensaries in Moscow with the allocation of groups of patients with diagnoses of SSD (F20—F25 according to ICD-10) was carried out. Among these groups, a targeted search for patients with an established diagnosis of PD (G20) was conducted. Among this category of patients, the incidence of PD, the therapy taken, the premotor symptoms of PD and the parameters characterizing the features of the clinical picture and diagnosis of PD were analyzed. Results. A total of 9124 patients with SSD were identified, among them 11 people diagnosed with PD, while the final incidence of PD was 0.1% (95% CI 0—0.2%). The average age at onset of SSD and PD was 33.18±8.72 years and 58.9±8.1 years, respectively. The average time between the appearance of the first signs of PD and the final diagnosis was 5.09±1.92 years. The most commonly used antipsychotic in the group of patients with PD was quetiapine (54.5%); clozapine and some typical antipsychotics were used less frequently. The most common premotor symptoms were apathy, depression, anxiety, constipation and orthostatic hypotension. Hyposmia and behavioral disorders in the REM sleep phase were less common. Conclusion. The results confirm the difficulty of managing patients with comorbidity of PD and SSD. Psychiatrists should pay close attention to the features of motor symptoms in patients with SSD and carefully identify clinical signs that may indicate the presence of PD or other neurodegenerative diseases with parkinsonism.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (11) , 30-33
Swimming disorders in Parkinson’s disease
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить нарушения навыков плавания у пациентов с болезнью Паркинсона (БП). МАТЕРИАЛ И МЕТОДЫ В ходе пилотного исследования нами обследованы 40 пациентов с БП, которые были разделены на 2 группы в зависимости от наличия или отсутствия нарушений навыков плавания. Оценка по шкале Хен—Яра в обеих группах колебалась от 1 до 3. Проводилась оценка степени тяжести БП по унифицированной шкале болезни Паркинсона Международного общества расстройств движений (MDS-UPDRS). Были использованы Монреальская шкала оценки когнитивных функций, госпитальная шкала тревоги и депрессии, новый опросник застываний при ходьбе, тест 6-минутной ходьбы, личностный опросник Айзенка. РЕЗУЛЬТАТЫ Из 40 пациентов с БП 60% отмечали нарушения навыков плавания. Не было обнаружено связи между нарушениями навыков плавания и выраженностью двигательных симптомов БП. В то же время в группе пациентов с нарушениями навыков плавания отмечен повышенный уровень тревожности. ЗАКЛЮЧЕНИЕ Необходимы дальнейшие исследования для изучения механизмов развития нарушений навыков плавания при БП.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (11) , 30-33
Swimming disorders in Parkinson’s disease
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить нарушения навыков плавания у пациентов с болезнью Паркинсона (БП). МАТЕРИАЛ И МЕТОДЫ В ходе пилотного исследования нами обследованы 40 пациентов с БП, которые были разделены на 2 группы в зависимости от наличия или отсутствия нарушений навыков плавания. Оценка по шкале Хен—Яра в обеих группах колебалась от 1 до 3. Проводилась оценка степени тяжести БП по унифицированной шкале болезни Паркинсона Международного общества расстройств движений (MDS-UPDRS). Были использованы Монреальская шкала оценки когнитивных функций, госпитальная шкала тревоги и депрессии, новый опросник застываний при ходьбе, тест 6-минутной ходьбы, личностный опросник Айзенка. РЕЗУЛЬТАТЫ Из 40 пациентов с БП 60% отмечали нарушения навыков плавания. Не было обнаружено связи между нарушениями навыков плавания и выраженностью двигательных симптомов БП. В то же время в группе пациентов с нарушениями навыков плавания отмечен повышенный уровень тревожности. ЗАКЛЮЧЕНИЕ Необходимы дальнейшие исследования для изучения механизмов развития нарушений навыков плавания при БП.